Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10542 Phase I in Healthy Participants
NCT07040046Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-10542 in paroxysmal nocturnal hemoglobinuria (PNH) and immunoglobulin A nephropathy (IgAN) (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Incidence and severity of adverse events. Started May 2025; status: recruiting.
02
Drugs
HS-10542
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07040046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040046.